IAVI C002

Status:Completed
Phase:I
Principal Investigator(s):David Ho, Michael Keefer, Soe Than
Objective:The purpose of this study is to determine the safety of an immune response to an investigational HIV vaccine, ADMVA, at three different dosage levels, in adults who are not infected with HIV   Last updated March 31, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionADMVA (MVA vector expressing HIV clade C env, gag, pol, nef, and tat) dosage escalation
Mode of Delivery
ARMsExperimental
Results: Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine
Official Code: NCT00252148
Related Publications:
Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review
Trial Sponsors: Aaron Diamond AIDS Research Center, IAVI, University of Rochester
Start Date
End Date
January 31, 2005
August 31, 2007
Enrollment:48
Age range: 18 Years ↔ 40 Years
Population:Cisgender Men, Cisgender Women